BMRA · Biomerica Inc. Common Stock
View on chartInsiders & Stakes
| Irani Zackary S. Chief Executive Officer | ▲ Buy | Open Market | 242,570 Shares held | 8/26/2026 | View profile |
| Emerson Jane Director | ▲ Buy | Grant | 156,000 Shares held | 12/13/2024 | View profile |
| Coste Catherine Director | ▲ Buy | Grant | 128,790 Shares held | 12/13/2024 | View profile |
| BARBIERI ALLEN Executive Vice Chairman | ▲ Buy | Open Market | 73,542 Shares held | 8/26/2026 | View profile |
| Lu Gary Chief Financial Officer | ▲ Buy | Grant | 59,375 Shares held | 12/12/2025 | View profile |
| Gary M. Huff Director | ▲ Buy | Open Market | 51,250 Shares held | 8/20/2026 | View profile |
| MOATAZEDI DAVID See Remarks | ▲ Buy | Open Market | 40,625 Shares held | 8/26/2026 | View profile |
| Chin Eric Chief Financial Officer | ▲ Buy | Open Market | 38,750 Shares held | 8/26/2026 | View profile |
Transaction History
| BARBIERI ALLEN | ▲ Buy | Open Market | 20,000 | $32K | 8/26/2026 |
| Irani Zackary S. | ▲ Buy | Open Market | 31,250 | $50K | 8/26/2026 |
| MOATAZEDI DAVID | ▲ Buy | Open Market | 10,000 | $16K | 8/26/2026 |
| Chin Eric | ▲ Buy | Open Market | 6,250 | $10K | 8/26/2026 |
| Gary M. Huff | ▲ Buy | Open Market | 31,250 | $50K | 8/20/2026 |
| Gary M. Huff | ▲ Buy | Grant | 20,000 | $0 | 12/12/2025 |
| MOATAZEDI DAVID | ▲ Buy | Grant | 20,000 | $0 | 12/12/2025 |
| BARBIERI ALLEN | ▲ Buy | Grant | 30,000 | $0 | 12/12/2025 |
| Irani Zackary S. | ▲ Buy | Grant | 52,500 | $0 | 12/12/2025 |
| Lu Gary | ▲ Buy | Grant | 40,000 | $0 | 12/12/2025 |
| Chin Eric | ▲ Buy | Grant | 22,500 | $0 | 12/12/2025 |
| Emerson Jane | ▲ Buy | Grant | 85,000 | $26K | 12/13/2024 |
| MOATAZEDI DAVID | ▲ Buy | Grant | 85,000 | $26K | 12/13/2024 |
| BARBIERI ALLEN | ▲ Buy | Grant | 110,000 | $34K | 12/13/2024 |
| Lu Gary | ▲ Buy | Grant | 155,000 | $48K | 12/13/2024 |
| Coste Catherine | ▲ Buy | Grant | 85,000 | $26K | 12/13/2024 |
| Irani Zackary S. | ▲ Buy | Grant | 250,000 | $78K | 12/13/2024 |
| Irani Zackary S. | ▲ Buy | Open Market | 200 | $310 | 5/25/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 500 | $805 | 5/24/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 1,700 | $2K | 5/12/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 500 | $635 | 5/10/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 300 | $417 | 5/9/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 1,000 | $1K | 5/4/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 1,800 | $2K | 4/28/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 2,600 | $3K | 4/27/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 7,000 | $9K | 4/26/2023 |
| BARBIERI ALLEN | ▲ Buy | Open Market | 1,538 | $5K | 1/27/2023 |
| Coste Catherine | ▲ Buy | Open Market | 2,190 | $6K | 1/26/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 1,800 | $5K | 1/25/2023 |
| Irani Zackary S. | ▲ Buy | Open Market | 2,000 | $6K | 1/24/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Biomerica reports Q1 earnings with lower EPS and sales
Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.
Biomerica reports Q1 earnings with lower EPS and sales. Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.